VTVT

vTv Therapeutics Inc. VTVT

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $12.4M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Revenue

$0

Quarter to Jun 30

Net income

$-13.05M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$60.51M total
Samsara BioCapital, LLC
$11.24M0.0%
MILLENNIUM MANAGEMENT LLC
$10.16M+30.8%
FMR LLC
$9.80M0.0%
Siren, L.L.C.
$6.14M0.0%
BAKER BROS. ADVISORS LP
$5.58M0.0%
VANGUARD CAPITAL MANAGEMENT LLC
$3.56M-13.3%
Trails Edge Capital Partners, LP
$3.21M-39.0%
Aisling Capital Management LP
$1.88MNew
MARSHALL WACE, LLP
$1.49M+195.5%
GEODE CAPITAL MANAGEMENT, LLC
$1.22M-1.3%
RENAISSANCE TECHNOLOGIES LLC
$657.1KNew
VANGUARD FIDUCIARY TRUST CO
$611.4K+0.7%
BlackRock, Inc.
$554.6K+16.9%
JANE STREET GROUP, LLC
$515.9KNew
STATE STREET CORP
$461.8K+15.0%
TWO SIGMA INVESTMENTS, LP
$432.4KNew
Verdad Advisers, LP
$338.7KNew
Integrated Quantitative Investments LLC
$309.1KNew
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$302.1KNew
Quadrature Capital Ltd
$237.4KNew
Trexquant Investment LP
$234.9KNew
NORTHERN TRUST CORP
$230.5K-66.1%
Pathstone Holdings, LLC
$228.7K0.0%
Point72 Asset Management, L.P.
$223.9KNew
HRT FINANCIAL LP
$223.0KNew
See all 45 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/VTVT

Loading ratio trend…

VTVT key financials by period

Reported revenue, net income and operating margin by fiscal year, from vTv Therapeutics Inc.'s annual filings on SEC EDGAR.

vTv Therapeutics Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2024$1.0M$-18.5M—
FY 2022$2.0M$-19.2M—
FY 2021$4.0M$-13.0M—
FY 2020$6.4M$-8.5M-184.8%
FY 2019$2.8M$-13.0M—
FY 2018$12.4M$-7.9M-159.4%
Source: VTVT filings on SEC EDGAR →

VTVT insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About vTv Therapeutics Inc. (VTVT): stock profile, AI score and financials

vTv Therapeutics Inc. (VTVT) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. VTVT is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $12.4m in revenue and is scored on the micro-cap board instead. Top institutional holders of VTVT by reported 13-F value include Samsara BioCapital, MILLENNIUM MANAGEMENT, FMR, based on the most recent SEC filings. VTVT trades on the Nasdaq exchange and files with the SEC under CIK 1641489. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VTVT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for vTv Therapeutics Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1641489 →